Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Aug 14, 2024 9:36pm
76 Views
Post# 36179767

RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

August 12, 2024 - Oncology, rare diseases, and immunology will likely continue to be hot targets for investors, and snapping up drugs from smaller startups has advantages over in-house development.  

“What we’re seeing is the elimination of riskier and longer-shot products in the R&D portfolio for the big pharma companies, basically swapping those out for acquisitions with more potential than the products they’re cutting,” according to Michael Abrams , Managing Partner, Numerof & Associates.  

And in terms of cash to make these deals, Big Pharma has it. Many companies are sitting on substantial war chests from the successful products that they’ve had over the last decade, Abrams said. In 2023, companies had about $1.37 trillion available to deploy

“It’s going to be a very active M&A story over the balance of the year and into next year,” Abrams said.

<< Previous
Bullboard Posts
Next >>